Related Experiment Video

Updated: Nov 17, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.1K

The Safety of The Directly Acting Antiviral Treatment For Hepatitis C Virus According To The Egyptian National

Ahmed Farouk Alaarag1, Ahmed Mohamed Hamam2, Osama Ahmed Amin3

  • 1Department of Cardiology Tanta University, EG.

Global Heart
|February 18, 2021
PubMed

Insights

Directly acting antiviral agents for hepatitis C virus are safe for patients with midrange heart function. Treatment showed no adverse cardiovascular effects and improved insulin resistance.

Area of Science:

  • Cardiology
  • Hepatology
  • Pharmacology

Background:

  • The Egyptian National Committee of Viral Hepatitis leads global hepatitis C virus (HCV) management.
  • Limited data exists on the cardiovascular effects of new directly acting antiviral agents (DAAs).

Purpose of the Study:

  • To assess the cardiovascular safety of DAAs in HCV patients with midrange left ventricular ejection fraction (LVEF).

Main Methods:

  • A multicenter study of 400 HCV patients (LVEF 40-49%) treated with Sofosbuvir/Daclatasvir (Group I) or Sofosbuvir/Daclatasvir/Ribavirin (Group II).
  • Evaluations included cardiac function, biomarkers (BNP), metabolic profiles, and Holter monitoring before and after treatment.

Main Results:

  • No significant changes in cardiac function (NYHA Class, LVEF, BNP) or heart rate variability were observed.
  • DAA treatment did not induce bradycardia or non-sustained ventricular tachycardia.
  • Improved insulin resistance and decreased glucose/insulin levels were noted; HDL/LDL increased in Group II.

Conclusions:

  • DAA regimens are safe for HCV patients with NYHA Class I/II and midrange LVEF (40-49%).
  • HCV clearance with DAAs leads to beneficial metabolic changes, including improved insulin resistance.
Abstract

Keywords:
Directly Acting Antiviral AgentsHepatitis C VirusMidrange Left Ventricular Ejection Fraction

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

824
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.7K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
100
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
76
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
80
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
88
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
70